

Rheumatic Heart Disease Management Market Soars at 4.5% CAGR to Reach US\$ 2.04 Billion by 2033 | FMI Study

Global Rheumatic Heart Disease Management Market Thrives on Cardiovascular Disease Prevalence, Geriatric Population, Dual Therapy, and Government Initiatives.



NEWARK, DELAWARE, UNITED STATES OF AMERICA, November 8, 2023 /EINPresswire.com/ -- The global [Rheumatic-Heart Disease Management market](#) size is expected to be valued at US\$ 1.31 Billion in 2023. With the continuous improvements in drugs and biotechnology, the overall demand for Rheumatic-Heart Disease Management is projected to grow at a CAGR of 4.5% between 2023 and 2033, totaling around US\$ 2.04 Billion by 2033.

The rising prevalence of cardiovascular diseases globally is one of the major factors that is expected to fuel the growth of the rheumatic heart disease management market during the forecast period. The growing geriatric population has also been influencing the market growth. Acute pericarditis is the most common rheumatic heart disease in several clinical settings, according to Cureus, an open access medical journal for a new generation of doctors and patients.

Request Your Sample Report: <https://www.futuremarketinsights.com/reports/sample/rep-gb-16349>

Acute pericarditis has been reported to affect between 0.1 and 0.2% of hospitalized patients, with 5% of patients admitted to the emergency department with non-ischemic chest pain. In addition, cardiovascular diseases kill 17.9 million people globally each year, accounting for an estimated 31% of all deaths. Further, low- and middle-income countries account for more than 75% of cardiovascular deaths. The use of dual therapy to treat rheumatic heart disease is another factor accelerating the market growth.

Additionally, increased alcohol consumption and smoking, and lifestyle changes are other factors that contribute to the rise in cardiovascular diseases, as well as the rheumatic heart disease management market. More emphasis on the prevention and treatment of cardiovascular diseases in low- and middle-income countries is projected to propel the revenue share of the market over the analysis period.

Rising environmental pollution, which leads to a higher prevalence of viral and fungal infection is another factor driving the market growth. In addition, the government's increased healthcare spending to combat the growing incidence of rheumatic fever, which is also fueling the market growth. Moreover, the leading market players' continuous improvements in Rheumatic heart disease drug and biotechnology growth have been creating lucrative opportunities in the rheumatic heart disease market. Other major factors that are anticipated to escalate the market growth include the rising incidence of chronic diseases including cardiovascular diseases, diabetes mellitus type 2, among others.

Key Takeaways from the Rheumatic-Heart Disease Management Market Study:

Global Rheumatic-Heart Disease Management Market was valued at US\$ 1.25 Billion by 2022-end. From 2018 to 2022, the market demand expanded at a CAGR of 2.1%.

By Type, the Valve segment of the market constitutes the bulk of the market with a market share of 46%.

By Application, the Hospitals segment dominates the market with a share of 46%.

From 2023 to 2033, Rheumatic-Heart Disease Management sales are expected to flourish at a CAGR of 4.5%.

By 2033, the market value of Rheumatic-Heart Disease Management is expected to reach US\$ 04 Billion.

An upsurge in financial support to researchers for developing new innovative drugs for treatment of rheumatic fever, coupled with growing geriatric population are expected to fuel the Rheumatic-Heart Disease Management Market in the forthcoming years, remarks an Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)

Recent Developments in the Rheumatic-Heart Disease Management market:

In September 2019, Medtronic announced the launch of Evolut PRO+, a transcatheter aortic valve replacement (TAVR) system in the U.S.

In September 2019, Abbott initiated the TRILUMINATE pivotal trial for the evaluation of TriClip, a transcatheter tricuspid valve repair for treating tricuspid regurgitation.

Know More About What the Rheumatic-Heart Disease Management Market Report Covers

Future Market Insights offers an unbiased analysis of the global Rheumatic-Heart Disease Management Market, providing historical data for 2018-2022 and forecast statistics from 2023-

2033. To understand opportunities in the Rheumatic-Heart Disease Management Market, the market is segmented on the basis of type, and application, across five major regions.

About Healthcare at Future Market Insights

The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.

Top 23 Key Companies Profiled in the Rheumatic-Heart Disease Management Market:

Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Pfizer Inc.
GlaxoSmithKline plc.
Novartis AG
Bayer AG
Eli Lilly and Company
Merck & Co., Inc.
Allergan
AstraZeneca
AbbVie Inc.
Johnson & Johnson Private Limited
Cipla Inc.
Abbott
Merck KGaA
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
Reddy's Laboratories Ltd.
Glenmark Pharmaceuticals Limited
Amneal Pharmaceuticals LLC.
Bayer AG

Access Exclusive Market Insights - Purchase Now!

<https://www.futuremarketinsights.com/checkout/16349>

Key Segmentations

by Type:

Valve
Myocarditis
Pericarditis

by Application:

Hospital
Diagnostic Centre
Research Centre

Author by

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Have a Look at Related Reports of Covered in Rheumatic-Heart Disease Management Market:

[Prosthetic Heart Valve Market size](#) of US\$ 13,234.9 million by 2023, By 2033, the prosthetic heart valve market is expected to be valued at US\$ 27,277.6 million.

[Rare Disease Clinical Trials Market size](#) is projected to be valued at US\$ 12,566.14 million in 2023 and is expected to rise to US\$ 31,715.25 million by 2033.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Ankush Nikam
Future Market Insights, Inc.
+91 90966 84197

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/667051971>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.